Interleukin Genetics (ILIU) 0.1450 $ILIU
Interleukin's (ILIU) CEO Mark Carbeau on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri May 15, 9:21AM CDT
Interleukin Genetics Reports First Quarter 2015 Financial Results
Business Wire - Fri May 15, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal first quarter of 2015 ended March 31, 2015.
Interleukin Genetics Announces Conference Call to Discuss First Quarter 2015 Financial Results
Business Wire - Mon May 11, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, May 15, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's first quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company's website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
Interleukin Genetics Granted Key European Patent Covering Inherent Health(R) Weight Management Genetic Test
Business Wire - Wed Apr 15, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that it has been granted a patent by the European Patent Office (EPO) covering the Company's Inherent Health(R) Weight Management Genetic Test. The granted patent, entitled "Genetic Markers for Weight Management and Methods of Use Thereof," has claims covering methods of determining a subject's metabolic genotype and methods for selecting an appropriate therapeutic/dietary regimen or lifestyle recommendation based on the subject's metabolic profile and susceptibility to adverse weight management issues. The European patent grants coverage of the Weight Management Genetic Test into 2029. Corresponding patents have been granted in major markets throughout the world including Eurasia, Japan, Mexico, Russia and New Zealand, and patent applications are pending in the U.S. and other major markets.
Interleukin Genetics Appoints Mark B. Carbeau as CEO
Business Wire - Tue Apr 07, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced the appointment of Mark B. Carbeau as Chief Executive Officer and Director. Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief Scientific Officer and a Director.
Interleukin Genetics Collaborators Present Scientific Research Supporting Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting
GlobeNewswire - Wed Apr 01, 10:50AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced two late-breaking poster presentations supporting its Inherent Health(R) Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting taking place March 28 - April 1, 2015, in Boston.
Interleukin Genetics and Employee Benefit Consulting Group LLC Partner to Expand Awareness and Adoption of PerioPredict(R)
Business Wire - Mon Mar 30, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) and Employee Benefit Consulting Group LLC (EBCG) announced today the signing of a collaboration agreement to help expand knowledge and potential coverage for Interleukin's novel genetic risk test, PerioPredict(R). PerioPredict(R) is an innovative, easy-to-use tool that identifies individuals with a higher risk of progressing to severe periodontal disease.
Interleukin Genetics' (ILIU) CEO Kenneth Kornman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 20, 1:00PM CDT
Interleukin Genetics Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Fri Mar 20, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2014.
Interleukin Genetics Presents at Two Medical and Industry Conferences
Business Wire - Mon Mar 16, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that Kenneth S. Kornman, DDS, Ph.D., Chief Executive Officer of Interleukin Genetics, has presented at the following recent conferences:
Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Mon Mar 16, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, March 20, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's fourth quarter and year-end 2014 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company's website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
Interleukin 1 Gene Variations Interact With Obesity to Predict Periodontitis Progression
Business Wire - Thu Mar 12, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today a poster presentation at the 2015 International Association for Dental Research General Session & Exhibition, taking place March 11-14, 2015, in Boston. The poster (#1290), titled "IL1 Genotype and Obesity Characteristics Interact to Influence Periodontitis Progression," will be presented by Leon Williams, Ph.D., Senior Director of Translational Sciences, Interleukin Genetics, on Thursday, March 12, from 2:00-3:15 p.m. (ET).
Interleukin Genetics Expands its Collaboration with Isis Pharmaceuticals for Genetic Testing Services
Business Wire - Mon Mar 09, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that under the terms of its collaboration agreement with Isis Pharmaceuticals, the Company will provide Isis with testing kits and will prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis' Phase 1 clinical study evaluating its novel therapeutic, ISIS-APO(a)-LRx in healthy volunteers with elevated lipoprotein(a), or Lp(a). Lp(a) is an independent risk factor for cardiovascular disease. This Phase I study is the second Isis clinical study to incorporate Interleukin's genetic test into the trial design to add genetic information at the earliest phases of testing of their new product lines.
ISIS: 64.33 (+1.78)
Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services
Business Wire - Wed Jan 07, 7:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today an agreement with Isis Pharmaceuticals Inc. to provide genetic testing services for Isis' Phase 2 clinical study evaluating its novel therapeutic, ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.
ISIS: 64.33 (+1.78)
Interleukin's PerioPredict(R) Genetic Test Featured in Genome Magazine
Business Wire - Mon Jan 05, 7:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that an article, titled "Dentistry Gets Personalized," has been published online in Genome magazine. The article, which also appeared in the Fall 2014 print issue, includes an overview of Interleukin's novel genetic test, PerioPredict(R), and its utility in identifying a patient's risk for severe periodontal disease based on the individual's genetic profile as well as its role in advancing personalized medicine in dentistry.
Horizon Technology Finance Provides $5 Million Venture Loan to Interleukin Genetics
eTeligis - Tue Dec 30, 3:16PM CST
FARMINGTON, CT and WALTHAM, MA, United States, via ETELIGIS INC., 12/30/2014 - - Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"
, a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, today announced it has closed a $5 million venture loan for Interleukin Genetics, Inc. (OTCQB: ILIU) ("Interleukin", a genetics-based personalized health testing company. Interleukin will use the proceeds for working capital purposes.
HRZN: 14.12 (unch)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 140.28 (+0.17), SKBI: 3.16 (-0.22), PTBI: 9.27 (+1.29), FMD: 6.59 (+0.13), GHC: 1,015.89 (+24.07), VRML: 1.93 (+0.07), ADBE: 79.41 (+0.49), OHAI: 5.70 (+0.02), KERX: 10.50 (+0.17), BH: 356.85 (+3.78), LII: 114.03 (-0.03), JAZZ: 180.06 (+2.05), NMBL: 25.54 (+0.48), REGN: 496.74 (+7.73), OAS: 17.36 (+0.14), XLRN: 32.68 (+0.84), SYK: 96.59 (+1.08), CRM: 72.80 (+0.40)
Interleukin Genetics Raises $10 Million in Financings
Business Wire - Tue Dec 23, 3:01PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has entered into a Securities Purchase Agreement with various accredited investors to raise gross proceeds of $5.0 million in a private placement financing. The syndicate is comprised of new and existing investors including two leading life sciences investment firms, New Enterprise Associates (NEA) and Bay City Capital.
HRZN: 14.12 (unch)
Interleukin's (ILIU) CEO Mark Carbeau on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri May 15, 9:21AM CDT
Interleukin Genetics Reports First Quarter 2015 Financial Results
Business Wire - Fri May 15, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal first quarter of 2015 ended March 31, 2015.
Interleukin Genetics Announces Conference Call to Discuss First Quarter 2015 Financial Results
Business Wire - Mon May 11, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, May 15, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's first quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company's website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
Interleukin Genetics Granted Key European Patent Covering Inherent Health(R) Weight Management Genetic Test
Business Wire - Wed Apr 15, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that it has been granted a patent by the European Patent Office (EPO) covering the Company's Inherent Health(R) Weight Management Genetic Test. The granted patent, entitled "Genetic Markers for Weight Management and Methods of Use Thereof," has claims covering methods of determining a subject's metabolic genotype and methods for selecting an appropriate therapeutic/dietary regimen or lifestyle recommendation based on the subject's metabolic profile and susceptibility to adverse weight management issues. The European patent grants coverage of the Weight Management Genetic Test into 2029. Corresponding patents have been granted in major markets throughout the world including Eurasia, Japan, Mexico, Russia and New Zealand, and patent applications are pending in the U.S. and other major markets.
Interleukin Genetics Appoints Mark B. Carbeau as CEO
Business Wire - Tue Apr 07, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced the appointment of Mark B. Carbeau as Chief Executive Officer and Director. Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief Scientific Officer and a Director.
Interleukin Genetics Collaborators Present Scientific Research Supporting Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting
GlobeNewswire - Wed Apr 01, 10:50AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced two late-breaking poster presentations supporting its Inherent Health(R) Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting taking place March 28 - April 1, 2015, in Boston.
Interleukin Genetics and Employee Benefit Consulting Group LLC Partner to Expand Awareness and Adoption of PerioPredict(R)
Business Wire - Mon Mar 30, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) and Employee Benefit Consulting Group LLC (EBCG) announced today the signing of a collaboration agreement to help expand knowledge and potential coverage for Interleukin's novel genetic risk test, PerioPredict(R). PerioPredict(R) is an innovative, easy-to-use tool that identifies individuals with a higher risk of progressing to severe periodontal disease.
Interleukin Genetics' (ILIU) CEO Kenneth Kornman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 20, 1:00PM CDT
Interleukin Genetics Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Fri Mar 20, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2014.
Interleukin Genetics Presents at Two Medical and Industry Conferences
Business Wire - Mon Mar 16, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that Kenneth S. Kornman, DDS, Ph.D., Chief Executive Officer of Interleukin Genetics, has presented at the following recent conferences:
Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Mon Mar 16, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, March 20, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's fourth quarter and year-end 2014 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company's website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
Interleukin 1 Gene Variations Interact With Obesity to Predict Periodontitis Progression
Business Wire - Thu Mar 12, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today a poster presentation at the 2015 International Association for Dental Research General Session & Exhibition, taking place March 11-14, 2015, in Boston. The poster (#1290), titled "IL1 Genotype and Obesity Characteristics Interact to Influence Periodontitis Progression," will be presented by Leon Williams, Ph.D., Senior Director of Translational Sciences, Interleukin Genetics, on Thursday, March 12, from 2:00-3:15 p.m. (ET).
Interleukin Genetics Expands its Collaboration with Isis Pharmaceuticals for Genetic Testing Services
Business Wire - Mon Mar 09, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that under the terms of its collaboration agreement with Isis Pharmaceuticals, the Company will provide Isis with testing kits and will prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis' Phase 1 clinical study evaluating its novel therapeutic, ISIS-APO(a)-LRx in healthy volunteers with elevated lipoprotein(a), or Lp(a). Lp(a) is an independent risk factor for cardiovascular disease. This Phase I study is the second Isis clinical study to incorporate Interleukin's genetic test into the trial design to add genetic information at the earliest phases of testing of their new product lines.
ISIS: 64.33 (+1.78)
Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services
Business Wire - Wed Jan 07, 7:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today an agreement with Isis Pharmaceuticals Inc. to provide genetic testing services for Isis' Phase 2 clinical study evaluating its novel therapeutic, ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.
ISIS: 64.33 (+1.78)
Interleukin's PerioPredict(R) Genetic Test Featured in Genome Magazine
Business Wire - Mon Jan 05, 7:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that an article, titled "Dentistry Gets Personalized," has been published online in Genome magazine. The article, which also appeared in the Fall 2014 print issue, includes an overview of Interleukin's novel genetic test, PerioPredict(R), and its utility in identifying a patient's risk for severe periodontal disease based on the individual's genetic profile as well as its role in advancing personalized medicine in dentistry.
Horizon Technology Finance Provides $5 Million Venture Loan to Interleukin Genetics
eTeligis - Tue Dec 30, 3:16PM CST
FARMINGTON, CT and WALTHAM, MA, United States, via ETELIGIS INC., 12/30/2014 - - Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"
, a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, today announced it has closed a $5 million venture loan for Interleukin Genetics, Inc. (OTCQB: ILIU) ("Interleukin", a genetics-based personalized health testing company. Interleukin will use the proceeds for working capital purposes. HRZN: 14.12 (unch)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 140.28 (+0.17), SKBI: 3.16 (-0.22), PTBI: 9.27 (+1.29), FMD: 6.59 (+0.13), GHC: 1,015.89 (+24.07), VRML: 1.93 (+0.07), ADBE: 79.41 (+0.49), OHAI: 5.70 (+0.02), KERX: 10.50 (+0.17), BH: 356.85 (+3.78), LII: 114.03 (-0.03), JAZZ: 180.06 (+2.05), NMBL: 25.54 (+0.48), REGN: 496.74 (+7.73), OAS: 17.36 (+0.14), XLRN: 32.68 (+0.84), SYK: 96.59 (+1.08), CRM: 72.80 (+0.40)
Interleukin Genetics Raises $10 Million in Financings
Business Wire - Tue Dec 23, 3:01PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has entered into a Securities Purchase Agreement with various accredited investors to raise gross proceeds of $5.0 million in a private placement financing. The syndicate is comprised of new and existing investors including two leading life sciences investment firms, New Enterprise Associates (NEA) and Bay City Capital.
HRZN: 14.12 (unch)
